AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27663365 — intervention group
Group type: COMPARATOR
Intervention: Fibroblasts
Number of subjects: 15
Study 24785761 — intervention group
Group type: EXPERIMENTAL
Intervention: Striatal dopamine D2/3 receptor availability in obese subjects
Number of subjects: 30
Study 24785761 — intervention group
Group type: COMPARATOR
Intervention: Amphetamine-induced dopamine release in controls
Number of subjects: 30
Study 24785761 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine-induced dopamine release in obese subjects
Number of subjects: 30
Study 24785761 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of dopamine release between groups
Number of subjects: 30
Study 24785761 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of dopamine release with food craving in obese subjects
Number of subjects: 30
Study 22468623 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-killed Lactobacillus plantarum L-137 (10 mg tablet)
Number of subjects: 16
Study 22468623 — intervention group
Group type: COMPARATOR
Intervention: Control group (matching tablet)
Number of subjects: 16
Study 20212198 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching plus telescopic magnification
Number of subjects: 15
Study 20212198 — intervention group
Group type: COMPARATOR
Intervention: Patching alone
Number of subjects: 15
Study 18517083 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray, 110 microg once daily
Number of subjects: 183
Study 18517083 — intervention group
Group type: COMPARATOR
Intervention: Prednisone, 10 mg once daily
Number of subjects: 183
Study 18517083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 15860944 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender aromatherapy
Number of subjects: 0
Study 15860944 — intervention group
Group type: EXPERIMENTAL
Intervention: Jojoba oil massage
Number of subjects: 0
Study 15860944 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 0
Study 12406021 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterol-enriched margarine providing 3.2 g of plant sterols daily for 3 weeks
Number of subjects: 88
Study 12406021 — intervention group
Group type: COMPARATOR
Intervention: Control margarine for 3 weeks
Number of subjects: 88
Study 10591389 — intervention group
Group type: COMPARATOR
Intervention: High-intensity oral anticoagulants (INR, 2.8-4.8)
Number of subjects: 10056
Study 10591389 — intervention group
Group type: COMPARATOR
Intervention: Moderate oral anticoagulants (INR, 2-3)
Number of subjects: 10056
Study 10591389 — intervention group
Group type: COMPARATOR
Intervention: Moderate- to high-intensity oral anticoagulants (INR, >=2)
Number of subjects: 10056
Study 10591389 — intervention group
Group type: COMPARATOR
Intervention: Moderate- to high-intensity oral anticoagulants and aspirin
Number of subjects: 10056
Study 10591389 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity oral anticoagulants (INR, <2.0) and aspirin
Number of subjects: 10056
Study 7726444 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular, sugar-free chewing gum
Number of subjects: 104
Study 7726444 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum 2 mg
Number of subjects: 104
Study 7726444 — intervention group
Group type: COMPARATOR
Intervention: Control (overnight fast)
Number of subjects: 104
Study 2139175 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 42
Study 2139175 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 42
Study 7018181 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 25
Study 7018181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31485039 — intervention group
Group type: EXPERIMENTAL
Intervention: EyeCee One IOL
Number of subjects: 80
Study 31485039 — intervention group
Group type: COMPARATOR
Intervention: iMics1 IOL
Number of subjects: 80
Study 30732139 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with cup-type N95 respirator
Number of subjects: 23
Study 30732139 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with fold-type N95 respirator
Number of subjects: 23
Study 30732139 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with valve-type N95 respirator
Number of subjects: 23
Study 27265181 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine-rich whey protein beverage (LWH)
Number of subjects: 8
Study 27265181 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein (SOY)
Number of subjects: 8
Study 27265181 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein + 3 g HMB (HMB)
Number of subjects: 8
Study 27265181 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric carbohydrate (CHO)
Number of subjects: 8
Study 25412432 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Post‐Concussion Assessment and Cognitive Testing (ImPACT)
Number of subjects: 0
Study 24298492 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Cervical Flexor (DCF) training
Number of subjects: 30
Study 24298492 — intervention group
Group type: COMPARATOR
Intervention: Conventional Isometric Training (CIT)
Number of subjects: 30
Study 21793279 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg low molecular weight iron-dextran intravenously in two doses (Group A)
Number of subjects: 135
Study 21793279 — intervention group
Group type: COMPARATOR
Intervention: 800 mg daily for 30 days of iron protein-succinylate (Group B)
Number of subjects: 135
Study 19194455 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone earplugs
Number of subjects: 34
Study 19194455 — intervention group
Group type: COMPARATOR
Intervention: Control group (no earplugs)
Number of subjects: 34
Study 17324285 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement
Number of subjects: 37
Study 17324285 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (placebo cohort from literature)
Number of subjects: 37
Study 15220185 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity with IL-6 infusion (LO + IL-6)
Number of subjects: 6
Study 15220185 — intervention group
Group type: COMPARATOR
Intervention: Low intensity without IL-6 infusion (LO)
Number of subjects: 6
Study 15220185 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity (HI)
Number of subjects: 6
Study 12457389 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive interventions evaluated in the PACE Clinic program.
Number of subjects: 0
Study 12457389 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological and psychological processes investigated.
Number of subjects: 0
Study 10413652 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma (IFN-gamma) therapy
Number of subjects: 35
Study 10413652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 7560771 — intervention group
Group type: EXPERIMENTAL
Intervention: Biovisc (1% sodium hyaluronate)
Number of subjects: 106
Study 7560771 — intervention group
Group type: COMPARATOR
Intervention: Healonid
Number of subjects: 106
Study 1792112 — intervention group
Group type: EXPERIMENTAL
Intervention: Edu‐K movement
Number of subjects: 20
Study 1792112 — intervention group
Group type: EXPERIMENTAL
Intervention: Repatterned Edu‐K movements
Number of subjects: 20
Study 1792112 — intervention group
Group type: COMPARATOR
Intervention: Control group (sat quietly for 10 minutes)
Number of subjects: 20
Study 7171413 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemically administered diamorphine
Number of subjects: 0
Study 7171413 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal analgesia with 0.5% bupivacaine plain
Number of subjects: 0
Study 7171413 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal analgesia with 0.5% bupivacaine plain and morphine sulphate
Number of subjects: 0
Study 7171413 — intervention group
Group type: COMPARATOR
Intervention: Injected diamorphine
Number of subjects: 0
Study 29512121 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular ketorolac (5 mg)
Number of subjects: 44
Study 29512121 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 44
Study 26460629 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA (Sinemet®)
Number of subjects: 10
Study 26460629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 24261316 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg once daily added to gabapentin (maximum 2400 mg daily)
Number of subjects: 8
Study 24261316 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin monotherapy
Number of subjects: 8
Study 21431338 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem (RXU)
Number of subjects: 34
Study 21431338 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem with selective enamel etching (RXU+E)
Number of subjects: 34
Study 21309476 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg plain bupivacaine plus 25 mg meperidine (BM25)
Number of subjects: 80
Study 21309476 — intervention group
Group type: COMPARATOR
Intervention: 10 mg hyperbaric bupivacaine (HB)
Number of subjects: 80
Study 21309476 — intervention group
Group type: COMPARATOR
Intervention: 5 mg plain bupivacaine plus 35 mg meperidine (BM35)
Number of subjects: 80
Study 21309476 — intervention group
Group type: COMPARATOR
Intervention: 5 mg plain bupivacaine plus 30 mg meperidine (BM30)
Number of subjects: 80
Study 17599306 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metronidazole (250 mg 4 times per day) for 10 days
Number of subjects: 172
Study 17599306 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vancomycin (125 mg 4 times per day) for 10 days
Number of subjects: 172
Study 17599306 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metronidazole (250 mg 4 times per day)
Number of subjects: 172
Study 17599306 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vancomycin (125 mg 4 times per day)
Number of subjects: 172
Study 16301160 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate
Number of subjects: 0
Study 16301160 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate Restorative Material
Number of subjects: 0
Study 12088304 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold electrical stimulation (TES)
Number of subjects: 57
Study 12088304 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inactive stimulators)
Number of subjects: 57
Study 9696952 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine IV
Number of subjects: 122
Study 9696952 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine IV
Number of subjects: 122
Study 7730907 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (10-15 mg/kg/dose)
Number of subjects: 104
Study 7730907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 7730907 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 104
Study 2913806 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ml of 0.01% intracameral carbachol
Number of subjects: 32
Study 2913806 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 ml of 0.01% intracameral carbachol
Number of subjects: 32
Study 2913806 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 ml of 0.01% intracameral carbachol
Number of subjects: 32
Study 2913806 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (0.1 or 0.5 ml) - Control group
Number of subjects: 32
Study 31950604 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (up to 50 mg/day)
Number of subjects: 527
Study 31950604 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 527
Study 31307856 — intervention group
Group type: EXPERIMENTAL
Intervention: NASA Mission X (MX) program, 8-week intervention
Number of subjects: 245
Study 31307856 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 245
Study 28283797 — intervention group
Group type: COMPARATOR
Intervention: Conjugated linoleic acid (CLA)
Number of subjects: 0
Study 28283797 — intervention group
Group type: COMPARATOR
Intervention: Protandim
Number of subjects: 0
Study 28283797 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 0
Study 26304977 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 336
Study 26304977 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 336
Study 23382081 — intervention group
Group type: EXPERIMENTAL
Intervention: Gufoni liberatory maneuver (GLM)
Number of subjects: 72
Study 23382081 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 72
Study 21681118 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose gefitinib (250 mg daily)
Number of subjects: 114
Study 21681118 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose gefitinib (dose reduced due to toxicities)
Number of subjects: 114
Study 18549692 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate 100 mg daily for 9 days starting on day 2 of menses
Number of subjects: 318
Study 18549692 — intervention group
Group type: COMPARATOR
Intervention: Gonadotrophin 75 IU intramuscularly daily for 5 days starting on day 3 of menses
Number of subjects: 318
Study 16571154 — intervention group
Group type: EXPERIMENTAL
Intervention: High-phenol extra-virgin olive oil (high-EVOO; 592 mg total phenols/kg)
Number of subjects: 10
Study 16571154 — intervention group
Group type: COMPARATOR
Intervention: Low-phenol extra-virgin olive oil (low-EVOO; 147 mg/kg)
Number of subjects: 10
Study 16571154 — intervention group
Group type: EXPERIMENTAL
Intervention: High-phenol extra-virgin olive oil (high-EVOO)
Number of subjects: 10
Study 14506534 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position (n = 21)
Number of subjects: 42
Study 14506534 — intervention group
Group type: COMPARATOR
Intervention: Supine position (n = 21)
Number of subjects: 42
Study 10858346 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod (IQ) treatment
Number of subjects: 0
Study 9200356 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg rhSOD intratracheally
Number of subjects: 33
Study 9200356 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg rhSOD intratracheally
Number of subjects: 33
Study 9200356 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 33
Study 9200356 — intervention group
Group type: EXPERIMENTAL
Intervention: rhSOD treatment groups
Number of subjects: 33
Study 8433420 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy plus best medical care (n = 91)
Number of subjects: 189
Study 8433420 — intervention group
Group type: COMPARATOR
Intervention: Best medical care alone (n = 98)
Number of subjects: 189
Study 8433420 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (for patients with crescendo TIAs)
Number of subjects: 189
Study 3319013 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 23
Study 3319013 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 23
Study 31886592 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcrestal implants (1-3 mm)
Number of subjects: 11
Study 31886592 — intervention group
Group type: COMPARATOR
Intervention: Equicrestal implants
Number of subjects: 11
Study 31886592 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (G1 and G2)
Number of subjects: 11
Study 29733995 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC)
Number of subjects: 60
Study 29733995 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Ischemic Preconditioning (LIPC)
Number of subjects: 60
Study 29733995 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 60
Study 26934211 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation with destabilization devices
Number of subjects: 26
Study 26934211 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation without destabilization devices (control group)
Number of subjects: 26
Study 26361756 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial Extracorporeal Shock Wave Therapy (rESWT) combined with supervised exercises (SE)
Number of subjects: 144
Study 26361756 — intervention group
Group type: COMPARATOR
Intervention: Sham rESWT combined with supervised exercises (SE)
Number of subjects: 144
Study 23057435 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine 1%
Number of subjects: 50
Study 23057435 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound Pachymetry (USP)
Number of subjects: 50
Study 23057435 — intervention group
Group type: COMPARATOR
Intervention: SP‐3000P
Number of subjects: 50
Study 21769961 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 6
Study 21769961 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl Trinitrate (GTN)
Number of subjects: 6
Study 21769961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 19139363 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE+MPA (Conjugated Equine Estrogen with Medroxyprogesterone Acetate)
Number of subjects: 1403
Study 19139363 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE-Alone (Conjugated Equine Estrogen Alone)
Number of subjects: 1403
Study 19139363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1403
Study 16356358 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic lifestyle-modification intervention (40-hour educational course over 4 weeks)
Number of subjects: 348
Study 16356358 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 348
Study 15277161 — intervention group
Group type: COMPARATOR
Intervention: Reduced-fat salad dressing (6 g canola oil)
Number of subjects: 7
Study 15277161 — intervention group
Group type: COMPARATOR
Intervention: Full-fat salad dressing (28 g canola oil)
Number of subjects: 7
Study 15277161 — intervention group
Group type: COMPARATOR
Intervention: Fat-free salad dressing (0 g canola oil)
Number of subjects: 7
Study 10932511 — intervention group
Group type: EXPERIMENTAL
Intervention: Norgestrel 0.5 mg/day
Number of subjects: 64
Study 10932511 — intervention group
Group type: COMPARATOR
Intervention: Cyproterone acetate 1 mg/day
Number of subjects: 64
Study 9059197 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural morphine 0.06 mg kg‐1 at the end of surgery and a second dose 6 h later
Number of subjects: 40
Study 9059197 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) with i.v. morphine 0.2 mg kg‐1 after surgery
Number of subjects: 40
Study 9059197 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received PCA with morphine 0.04 mg kg‐1 i.v.
Number of subjects: 40
Study 8346593 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 70
Study 8346593 — intervention group
Group type: COMPARATOR
Intervention: Conventional antihypertensive treatment
Number of subjects: 70
Study 3732360 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg mexiletine
Number of subjects: 8
Study 3732360 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg mexiletine
Number of subjects: 8
Study 3732360 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg disopyramide
Number of subjects: 8
Study 3732360 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg disopyramide
Number of subjects: 8
Study 3732360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29078739 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of berberine, arbutin, and birch (group A)
Number of subjects: 0
Study 29078739 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of berberine, arbutin, birch, and forskolin (group B)
Number of subjects: 0
Study 29078739 — intervention group
Group type: COMPARATOR
Intervention: Proanthocyanidins (group C)
Number of subjects: 0
Study 27513312 — intervention group
Group type: EXPERIMENTAL
Intervention: MDRD equation
Number of subjects: 9308
Study 27513312 — intervention group
Group type: COMPARATOR
Intervention: CKD-EPI equation
Number of subjects: 9308
Study 24787968 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel after disease progression with abiraterone acetate
Number of subjects: 23
Study 22283620 — intervention group
Group type: EXPERIMENTAL
Intervention: Active LED phototherapy
Number of subjects: 0
Study 22283620 — intervention group
Group type: COMPARATOR
Intervention: Placebo LED phototherapy
Number of subjects: 0
Study 20920126 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional assist ventilation (PAV)
Number of subjects: 20
Study 20920126 — intervention group
Group type: COMPARATOR
Intervention: Breathing spontaneously (Control)
Number of subjects: 20
Study 18367689 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsivity education (RE)/prelinguistic milieu teaching (PMT)
Number of subjects: 51
Study 18367689 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 51
Study 16116958 — intervention group
Group type: EXPERIMENTAL
Intervention: PMA (phorbol 12‐myristate 13‐acetate)
Number of subjects: 0
Study 16116958 — intervention group
Group type: EXPERIMENTAL
Intervention: PMA and AP‐1 cis‐element decoy oligodeoxynucleotides (decoy ODNs)
Number of subjects: 0
Study 16116958 — intervention group
Group type: EXPERIMENTAL
Intervention: PMA and AP‐1 mutant decoy ODNs
Number of subjects: 0
Study 16116958 — intervention group
Group type: COMPARATOR
Intervention: Blank control
Number of subjects: 0
Study 12576305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger pretreatment (1,000 and 2,000 mg)
Number of subjects: 13
Study 12576305 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vasopressin infusion (0.1 and 0.2 U/min)
Number of subjects: 13
Study 12576305 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 13
Study 10380244 — intervention group
Group type: COMPARATOR
Intervention: Trained Teacher condition
Number of subjects: 759
Study 10380244 — intervention group
Group type: COMPARATOR
Intervention: Specialist condition
Number of subjects: 759
Study 10380244 — intervention group
Group type: COMPARATOR
Intervention: Health-related physical education program
Number of subjects: 759
Study 9051704 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin at standard therapeutic doses
Number of subjects: 7
Study 9051704 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin at standard therapeutic doses
Number of subjects: 7
Study 8229380 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliding screwplate
Number of subjects: 113